Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 2/20 | 0.39 |
| ▸ | GCG | P01275 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112974 | 0.91 | PPARD (0.46) | SMN1; SMN2TRPV1NPC1HPGDRAB9A | |
| SCHEMBL3112952 | 0.87 | GCGR (0.38) | LMNASMN1; SMN2TRPV1NPC1HPGD | |
| SCHEMBL3095263 | 0.86 | GCGR (0.57) | GCGRGCG | |
| SCHEMBL3100257 | 0.85 | GCGR (0.37) | SMN1; SMN2TRPV1NPC1HPGDRAB9A | |
| SCHEMBL3106979 | 0.84 | GCGR (0.43) | TRPV1GCGRGCGPPARD | |
| SCHEMBL3093701 | 0.81 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2TRPV1NPC1HPGD | |
| SCHEMBL3095636 | 0.79 | PPARD (0.40) | SMN1; SMN2TRPV1NPC1HPGDRAB9A | |
| SCHEMBL3112814 | 0.79 | PPARD (0.42) | SMN1; SMN2TRPV1NPC1HPGDRAB9A | |
| SCHEMBL3103092 | 0.79 | PPARD (0.41) | SMN1; SMN2TRPV1NPC1HPGDRAB9A | |
| SCHEMBL3095590 | 0.77 | MMP13 (0.44) | LMNASMN1; SMN2NPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | LMNA 2457/4885SMN1; SMN2 4692/4885TRPV1 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.